LMR Partners’s SELLAS Life Sciences SLS Stock Holding History

LMR Partners’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.64M	Buy	+450,000	New	+$3.11M	0.02%	557

Other funds holding SLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

LMR Partners's SLS Position: Q3 2017 in Review

LMR Partners sold out of SELLAS Life Sciences (SLS) in Q3 2017, closing a stake of 39 shares — an estimated $33K sold.

LMR Partners first reported a position in SLS in Q2 2017 and held it in 1 quarter. The position peaked at $33K in Q2 2017. 28 funds tracked by Wall St. Rank hold SLS as of Q3 2017.

LMR Partners reported no remaining SELLAS Life Sciences position as of Q3 2017 after selling out during the quarter.
LMR Partners sold 39 SELLAS Life Sciences shares in Q3 2017, an estimated $33K.
LMR Partners first reported a position in SELLAS Life Sciences in Q2 2017 and held it in 1 quarter.
LMR Partners's SELLAS Life Sciences position peaked at $33K in Q2 2017.
28 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2017.

Based on LMR Partners's 13F filing for Q3 2017, filed 9 Nov 2017.